Results 141 to 150 of about 107,589 (249)

S3 guideline diagnostics and therapy of alopecia areata – Part 1: Diagnostics and epidemiology

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary In the project funded by the Innovation Committee at the G‐BA, the S3 guideline for the diagnosis and treatment of AA was developed between 2023 and 2025. The interdisciplinary expert panel consisted of representatives from the German Dermatological Society, in particular from the Pediatric Dermatology Working Group, the Professional ...
Ulrike Blume‐Peytavi, Andria Constantinou, Tsenka Tomova‐Simitchieva, Adrian Tanew, Michael Sticherling, Hermann Girschick, Annika Vogt, Uwe Schwichtenberg, Uwe Gieler, André Märtens, Kerstin Zienert, Claudia Stenders, Ricardo Niklas Werner, Doris Wilborn   +13 more
wiley   +1 more source

Clinical Outcomes of Children With Autoimmune Hepatitis in Korea: A Nationwide Multicenter Study. [PDF]

J Korean Med Sci
Ahn JE, Ko JS, Moon JS, Choi S, Lee YJ, Lee EJ, Koh H, Choi HJ, Oh SH, Kim KM, Kang KS, Choe BH, Kim SH, Kim ES, Kim MJ, Kim SY, Lee KJ.   +16 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier, Ramon A. Hofmann, Michael Roden, Wolfgang Rathmann, Oliver Kuss   +4 more
wiley   +1 more source

Environmental triggers of autoimmune hepatitis: a clinical perspective from Yemeni patients. [PDF]

Front Immunol
Farie WQ, Bahaj SS, Al-Madhagi AK, Sher Ali S, Noman A, Alkassar WY.   +5 more
europepmc   +1 more source

Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Orforglipron is a novel small‐molecule, once daily oral non‐peptide GLP‐1 receptor agonist. The hepatic safety profile in adults with obesity or overweight and/or type 2 diabetes (T2D) across seven orforglipron Phase 3 clinical trials was assessed.
Sean Wharton, Adam Stefanski, Jiaxun Chen, Girish Rao, Elvis Asare Twum, Max Denning   +5 more
wiley   +1 more source

Serum immunoglobulin G levels in patients with cirrhosis due to autoimmune hepatitis or other etiologies. [PDF]

Eur J Gastroenterol Hepatol
Su Y, Wang Q, Sun X, Zhao X, Zhao X, Jia J, Shan S.   +6 more
europepmc   +1 more source

Outcomes of dengue infection in adults with underlying haematological diseases in Brazil during 2024 and 2025

British Journal of Haematology, EarlyView.
K. Tozatto‐Maio, V. Weihermann, C. W. Erthal, M. W. Araújo, C. R. Gomes, K. Caciola, L. Otuyama, J. Gasparini, H. R. Higashino, S. F. Costa, A. N. Duarte‐Neto, F. S. Seguro, P. R. Villaça, E. D. R. P. Velloso, S. F. M. Gualandro, Y. Nukui, V. Rocha   +16 more
wiley   +1 more source

Proteolytic remodelling of the extracellular matrix by pericytes

The FEBS Journal, EarlyView.
Pericytes are specialised perivascular cells intimately connected with endothelial cells and essential for the maintenance of vascular beds. They contribute to the formation and remodelling of the extracellular matrix by actively secreting proteases and protease inhibitors.
Tina Burkhard, Ella Milne, Kate Qian, Paola Campagnolo, Salvatore Santamaria   +4 more
wiley   +1 more source

COVID-19 vaccine-associated liver injury and autoimmune hepatitis: a case series. [PDF]

Ann Med Surg (Lond)
Mariyam N, Albitar MH, Shafqat A, FathAlrahman R, Fallatah HI, Abaalkhail F, Zahran AA, AlMahmoud A.   +7 more
europepmc   +1 more source

From hepatic to hematopoietic: LRH‐1's expanding cellular repertoire to the immune system

The FEBS Journal, EarlyView.
The nuclear receptor LRH‐1 is a well‐characterized regulator of endodermal tissue. Yet, increasing evidence indicates that LRH‐1, although expressed at low levels, is also a critical regulator of the hematopoietic system. LRH‐1 regulates the immune system by contributing to immune cell‐specific functions.
Lukas Meisinger, Alice Wiedmann, Rayan Hassan M. Elshikhidriss, Thomas Brunner   +3 more
wiley   +1 more source